Rifampicin

證據等級: L5

預測適應症: 10 個

Rifampicin: From Tuberculosis to Conjunctivitis

One-Sentence Summary

Rifampicin is a broad-spectrum antimycobacterial antibiotic whose established use — extensively documented across this evidence pack's clinical trial and literature records — is tuberculosis (and related mycobacterial) treatment. The TxGNN model predicts it may also be effective for Conjunctivitis, a repurposing direction currently supported by 0 clinical trials and 20 publications, most of which are historical, epidemiological, or case-based rather than direct comparative trials.

Quick Overview

Item	Content
Original Indication	Tuberculosis / mycobacterial infection (inferred from extensive anti-TB clinical trial and literature content in the evidence pack; no formal indication text was retrievable for this drug)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.95%
Evidence Level	L3
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank for this candidate. Based on the information present in this evidence pack, rifampicin is a DNA-dependent RNA polymerase inhibitor with broad-spectrum bactericidal activity, and its efficacy against mycobacterial infection is well established across dozens of clinical trials in this dataset.

The mechanistic link to conjunctivitis rests on rifampicin's known in vitro and historical clinical activity against ocular pathogens — including Chlamydia trachomatis (the causative organism of trachoma, a chronic follicular conjunctivitis) and select conjunctival bacteria such as Staphylococcus aureus and Neisseria meningitidis. Notably, topical rifampicin was investigated as an ophthalmic ointment for endemic trachoma as early as the 1970s, predating its current systemic anti-TB role, so the "new" indication is arguably a re-emergence of an older, narrower historical use rather than a truly novel mechanism.

However, the supporting literature is overwhelmingly epidemiological (pathogen/antibiotic-susceptibility surveys) or single-case reports (e.g., meningococcal conjunctivitis treated with adjunctive systemic rifampin), rather than modern controlled trials establishing rifampicin — oral, systemic, or topical — as an effective conjunctivitis therapy in a defined patient population.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1096630	1975	Controlled therapy trial	American Journal of Ophthalmology	Controlled trial in Tunisian schoolchildren comparing 1% rifampicin ointment, 1% tetracycline ointment, and 5% boric acid ointment for endemic trachoma; assessed via serial slit-lamp exams and cultures over 39 weeks
5411121	1970	Preclinical/pharmacology	Nature	Early evidence of anti-trachoma activity of rifampicin and rifamycin SV derivatives
5005929	1971	Review	Annals of Ophthalmology	Overview of rifampicin use in ophthalmology (abstract not available)
14686993	2003	Case report	Clinical Microbiology and Infection	6-year-old with primary meningococcal conjunctivitis treated with topical antibiotics followed by systemic rifampin once diagnosis confirmed; no complications
7806886	1994	Case series	The Journal of Infection	Three cases of primary meningococcal conjunctivitis with systemic sepsis; recommends combined topical/parenteral therapy plus chemoprophylaxis (e.g., rifampin) for close contacts
33457332	2020	Cohort (pathogen/susceptibility survey)	Advanced Biomedical Research	Bacterial etiology and antibiotic susceptibility survey of conjunctivitis isolates in Kashan, Iran
15228931	2004	Cohort (pathogen/susceptibility survey)	Anales de Pediatría	Identifies most prevalent bacterial conjunctivitis pathogens and antibiotic sensitivity patterns in a pediatric population
19941479	2010	Review	Current Medicinal Chemistry	Reviews neglected bacterial diseases including trachoma and Buruli ulcer; notes rifampin/streptomycin as the only effective combination for Buruli ulcer
21484175	2011	Cohort (pathogen/susceptibility survey)	Journal of Ophthalmic Inflammation and Infection	Bacteriologic and plasmid analysis of conjunctivitis-causing organisms in Lagos, Nigeria
10537781	1999	Review	Current Opinion in Ophthalmology	Reviews ocular manifestations of cat-scratch disease (Bartonella henselae), a differential-diagnosis consideration rather than direct rifampicin efficacy evidence

New Zealand Market Information

Rifampicin is currently not marketed in New Zealand under this evidence pack — 0 product authorizations are on file, so no product/dosage-form table can be produced.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-drug interaction data were not available in this evidence pack — the DDI query returned no results.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence Level L3 reflects mostly epidemiological cohort studies, single-case reports, and one dated (1975) controlled trachoma ointment trial — no modern trial establishes rifampicin as an effective conjunctivitis therapy in a defined route/dose. Combined with the drug's non-marketed status in New Zealand and the complete absence of package-insert safety data (a blocking gap for any initial safety review), the candidate cannot currently advance past a research question.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — currently blocking, required before any safety pre-evaluation
Confirmed mechanism of action data from DrugBank
Route/formulation compatibility analysis — existing evidence is split between oral/systemic use (meningococcal cases) and topical ophthalmic ointment (historical trachoma trials); the currently marketed formulation profile is undetermined
Modern comparative or controlled trial evidence specific to conjunctivitis treatment, rather than pathogen-susceptibility surveys or case reports
Clarification of the overlapping "conjunctivitis" / "conjunctivitis (disease)" / "acute contagious conjunctivitis" labels in the underlying disease ontology, which appear to fragment the same signal across multiple ranked candidates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.